Neurofilament-light chain (NfL) as a biomarker of response to higher-efficacy disease-modifying therapies

November 22, 2023

Recommend to a Colleague print

 

Includes data on NfL changes after initiation of fingolimod, ofatumumab, ocrelizumab, natalizumab, alemtuzumab and oral cladribine.

11 slides

Download the slide deck

Recommend to a Colleague

Related Posts

• CLINICAL CASES IN NEUROLOGY – A PERIMENOPAUSAL WOMAN WITH MIGRAINE AND HEAD TRAUMA
  May 25, 2026
• CLINICAL CASES IN NEUROLOGY: A 55-y.o. with new MRI lesions
  May 19, 2026
• Reducing PIRA with high-efficacy DMTs in MS
  May 11, 2026
• AAN DAILY HIGHLIGHTS – WEDNESDAY, APRIL 22, 2026
  April 22, 2026
• AAN DAILY HIGHLIGHTS – TUESDAY, APRIL 21, 2026
  April 21, 2026

Go back to home page